File downloaded on 2026-11-05
Source URL: https://medicines.health.europa.eu/veterinary/en/700000241271

Yarvitan (WD) 5 mg/ml - Oral solution

Not authorised

- Mitratapide

Product identification

Medicine name:
Yarvitan (WD) 5 mg/ml - Oral solution

Active substance:
Mitratapide

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Mitratapide
5.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Oral solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QA08AB90

Legal status of supply:
Medicinal product subject to medical prescription

Authorisation status:
Surrendered

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Janssen Pharmaceutica

Marketing authorisation date:
14/11/2006

Manufacturing sites for batch release:
Janssen Pharmaceutica

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:

14/11/2006

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet